Pharmaceutical

Blended solutions gain momentum and reveal untapped potential Blended solutions gain momentum and reveal untapped potential

“When we assessed current practices for building consumer audiences, they didn’t meet IQVIA’s standard for excellence and safety — so we created a new...

In the latest episode of the Health Matters podcast, former Food and Drug Administration Commissioner Scott Gottlieb joins Health@WPP’s Wendy Lund, GC...

The U.S. subsidiary of India’s Unichem Pharmaceuticals is voluntarily recalling one lot of the muscle relaxant cyclobenzaprine hydrochloride after a l...

German generics maker Stada has settled on a buyout by CapVest Partners, putting an end to its previously reported IPO ambitions. The CapVest deal cha...

Merck & Co. and Bayer’s Verquvo failed to deliver a composite cardiovascular benefit for certain patients with stable heart failure with reduced eject...

Ionis has hit a “home run,” according to analysts at Citi, with data in two phase 3 trials that show the ability of Tryngolza (olezarsen) to reduce tr...

While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nord...

United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a pivotal phase 3 win in idiopath...

More than three years after launching a new corporate structure, Novartis is still making changes to its organization. In the latest move to streamlin...